Trial Profile
Phase I/II, open label study of sequential Taxotere (docetaxel) and Gleevec (imatinib mesylate) in hormone refractory prostate cancer.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- 28 Jun 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 11 Jan 2011 Actual end date changed from Apr 2010 to May 2010 as reported by ClinicalTrials.gov.
- 14 May 2010 Actual patient number (24) added as reported by ClinicalTrials.gov.